The table below shows BridgeBio Pharma, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$197.28M
-$199.24M
-$219.54M
-$144.32M
-$160.63M
-$150.76M
Capital expenditure
$69.00K
$0.00
$695.00K
$12.00K
$859.00K
$1.96M
Investing cash flow
-$42.73M
-$1.59M
$22.75M
$12.30M
$138.62M
-$282.05M
Dividends paid
-
-
-
-
BBIO operating cash flow (10-K history)
BridgeBio Pharma, Inc. reported operating cash flow of -$445.91M for fiscal year 2025. That is up 14.4% from -$520.73M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$40.49M (FY 2017) to -$445.91M. Figures come from the company's audited annual reports as filed with the SEC.
